Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 51, Issue 9

Issues

Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis

Elisabetta Bandiera
  • Corresponding author
  • “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynaecologic Oncology, University of Brescia, Brescia, Italy
  • Elisabetta Bandiera and Laura Zanotti contributed equally to this work.
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Laura Zanotti
  • Corresponding author
  • “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynaecologic Oncology, University of Brescia, Brescia, Italy
  • Elisabetta Bandiera and Laura Zanotti contributed equally to this work.
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Aline S.C. Fabricio
  • Regional Centre for Biomarkers, Department of Clinical Pathology, Azienda ULSS 12 Veneziana, Venice, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Elisa Bucca
  • Regional Centre for Biomarkers, Department of Clinical Pathology, Azienda ULSS 12 Veneziana, Venice, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Elisa Squarcina / Chiara Romani
  • “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynaecologic Oncology, University of Brescia, Brescia, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Renata Tassi
  • “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynaecologic Oncology, University of Brescia, Brescia, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Eliana Bignotti
  • “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynaecologic Oncology, University of Brescia, Brescia, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Paola Todeschini
  • “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynaecologic Oncology, University of Brescia, Brescia, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Germana Tognon / Cesare Romagnolo / Massimo Gion
  • Regional Centre for Biomarkers, Department of Clinical Pathology, Azienda ULSS 12 Veneziana, Venice, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Enrico Sartori / Tiziano Maggino / Sergio Pecorelli
  • “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynaecologic Oncology, University of Brescia, Brescia, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Antonella Ravaggi
  • “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynaecologic Oncology, University of Brescia, Brescia, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2013-09-06 | DOI: https://doi.org/10.1515/cclm-2013-0151

Abstract

Background: Human epididymis protein 4 (HE4), kallikrein 6 (KLK6), osteopontin (OPN) and soluble mesothelin-related peptide (SMRP) are new promising biomarkers that could integrate CA125 in epithelial ovarian cancer (EOC) diagnosis. The autoantibody response to tumor antigens is a potential tool for improving the diagnostic performances of biomarkers. The aim of this study was to assess the diagnostic potential of these biomarkers in the form of free markers and immunocomplexed with immunoglobulin M (IgM). Moreover, we analyzed the association between these markers and clinico-pathological characteristics of EOC patients.

Methods: Serum and plasma samples of 60 healthy controls, 60 ovarian benign cysts, 60 endometriosis and 60 EOCs, collected before any treatment, were tested for CICs and free antigens by immunoassays.

Results: Immunocomplexes were characterized by poor sensitivity and specificity, since they allowed the detection only of a small number of EOC patients and were increased in patients with benign gynecological pathologies. However, the markers in the form of free antigens showed good diagnostic performances. Of note, CA125 and HE4 showed high sensitivity in the detection of the malignancy and HE4 emerged as a useful biomarker in differential diagnosis between EOC and endometriosis. Finally, elevated KLK6 and OPN, were associated with advanced FIGO stage, high grade disease, suboptimally debulked tumor and ascites.

Conclusions: This study confirms the diagnostic role of CA125, HE4, KLK6, OPN and SMRP, and for the first time showed that CA125, HE4, KLK6, OPN and SMRP immunocomplexed with IgM are not a potential tool for EOC diagnosis.

Keywords: biomarkers; diagnosis; epithelial ovarian cancer; IgM

References

  • 1.

    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212–36.CrossrefWeb of ScienceGoogle Scholar

  • 2.

    Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer. Clin Chim Acta 2013;415:341–5.Web of ScienceGoogle Scholar

  • 3.

    Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922–9.Google Scholar

  • 4.

    Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919–26.CrossrefGoogle Scholar

  • 5.

    Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15:274–81.CrossrefGoogle Scholar

  • 6.

    Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007;174:91–100.Google Scholar

  • 7.

    Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. J Am Med Assoc 2011;305:2295–303.Google Scholar

  • 8.

    Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC Jr. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012;118:91–100.Web of ScienceCrossrefPubMedGoogle Scholar

  • 9.

    Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012;22(Suppl 1):S5–8.Web of ScienceGoogle Scholar

  • 10.

    Yip P, Chen TH, Seshaiah P, Stephen LL, Michael-Ballard KL, Mapes JP, et al. Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One 2011;6:e29533.CrossrefWeb of ScienceGoogle Scholar

  • 11.

    Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, et al. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 2011;122:548–53.Web of ScienceGoogle Scholar

  • 12.

    Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer PLCO Project Team. Cancer Prev Res 2011;4:375–83.CrossrefWeb of ScienceGoogle Scholar

  • 13.

    Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011;4:365–74.CrossrefGoogle Scholar

  • 14.

    Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159–66.CrossrefWeb of ScienceGoogle Scholar

  • 15.

    Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 2010;136:1079–88.Web of ScienceCrossrefGoogle Scholar

  • 16.

    Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Seshaiah P, et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 2009;4:e4599.Web of ScienceCrossrefGoogle Scholar

  • 17.

    Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2872–81.Web of ScienceCrossrefPubMedGoogle Scholar

  • 18.

    Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065–72.CrossrefGoogle Scholar

  • 19.

    Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110:374–82.Web of ScienceCrossrefGoogle Scholar

  • 20.

    Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007;107:526–31.CrossrefWeb of ScienceGoogle Scholar

  • 21.

    Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15–3, CA 72–4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004;22:4059–66.CrossrefGoogle Scholar

  • 22.

    Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402–8.CrossrefWeb of ScienceGoogle Scholar

  • 23.

    Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev 2011;20:2496–506.Web of ScienceGoogle Scholar

  • 24.

    Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009;115:112–20.Web of ScienceCrossrefPubMedGoogle Scholar

  • 25.

    Szubert S, Michalak S, Szpurek D, Moszynski R, Krygowska-Zielinska J, Sajdak S. Anti-ovarian antibodies in sera of patients with ovarian tumors. Immunol Lett 2012;148:133–7.CrossrefPubMedGoogle Scholar

  • 26.

    Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010;193:859–68.Google Scholar

  • 27.

    Cramer DW, O’Rourke DJ, Vitonis AF, Matulonis UA, Dijohnson DA, Sluss PM, et al. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem 2010;56:1889–92.Google Scholar

  • 28.

    Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008;14:764–71.Web of ScienceCrossrefPubMedGoogle Scholar

  • 29.

    Nesterova M, Johnson N, Cheadle C, Cho-Chung YS. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006;1762:398–403.Google Scholar

  • 30.

    Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006;102:244–51.PubMedGoogle Scholar

  • 31.

    Barua A, Bradaric MJ, Kebede T, Espionosa S, Edassery SL, Bitterman P, et al. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. Am J Reprod Immunol 2007;57:243–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 32.

    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.CrossrefPubMedGoogle Scholar

  • 33.

    Castaldi F, Marino M, Beneduce L, Belluco C, De Marchi F, Mammano E, et al. Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int J Biol Markers 2005;20:204–8.PubMedGoogle Scholar

  • 34.

    Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, et al. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer 2005;103:2558–65.CrossrefPubMedGoogle Scholar

  • 35.

    Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006;119:735–40.CrossrefPubMedGoogle Scholar

  • 36.

    Beneduce L, Prayer-Galetti T, Giustinian AM, Gallotta A, Betto G, Pagano F, et al. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Cancer Detect Prev 2007;31:402–7.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 37.

    Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasiolo A, Tono N, et al. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. Eur J Clin Invest 2008;38:571–7.CrossrefWeb of ScienceGoogle Scholar

  • 38.

    Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137–48.PubMedCrossrefGoogle Scholar

  • 39.

    Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, et al. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int J Gynecol Cancer 2009;19:1015–21.Web of ScienceGoogle Scholar

  • 40.

    Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J. Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 2005;54:55–62.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 41.

    Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315–9.CrossrefWeb of ScienceGoogle Scholar

  • 42.

    Bordin L, Fiore C, Donà G, Andrisani A, Ambrosini G, Faggian D, et al. Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertil Steril 2010;94:1616–21.Web of ScienceGoogle Scholar

  • 43.

    Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49:521–5.Web of ScienceGoogle Scholar

  • 44.

    Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011;205:358.e1–6.Web of SciencePubMedGoogle Scholar

About the article

Corresponding authors: Dr. Elisabetta Bandiera and Dr. Laura Zanotti, Division of Gynaecologic Oncology, “Angelo Nocivelli”, Institute of Molecular Medicine, University of Brescia, Spedali Civili 1, 25123 Brescia, Italy, Phone: +39 0303996286, Fax: +39 0303996059


Received: 2013-02-26

Accepted: 2013-07-29

Published Online: 2013-09-06

Published in Print: 2013-09-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 51, Issue 9, Pages 1815–1824, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2013-0151.

Export Citation

©2013 by Walter de Gruyter Berlin Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Francesco Plotti, Federica Guzzo, Teresa Schirò, Corrado Terranova, Carlo De Cicco Nardone, Roberto Montera, Daniela Luvero, Giuseppe Scaletta, Salvatore Lopez, Stella Capriglione, Pierluigi Benedetti Panici, and Roberto Angioli
International Journal of Gynecologic Cancer, 2019, Volume 29, Number 4, Page 768
[2]
Matthew T. Briggs, Mark R. Condina, Manuela Klingler-Hoffmann, Georgia Arentz, Arun V. Everest-Dass, Gurjeet Kaur, Martin K. Oehler, Nicolle H. Packer, and Peter Hoffmann
PROTEOMICS - Clinical Applications, 2018, Page 1800099
[3]
Renée T. Fortner, Helena Schock, Charlotte Le Cornet, Anika Hüsing, Allison F. Vitonis, Theron S. Johnson, Raina N. Fichorova, Titilayo Fashemi, Hidemi S. Yamamoto, Anne Tjønneland, Louise Hansen, Kim Overvad, Marie-Christine Boutron-Ruault, Marina Kvaskoff, Gianluca Severi, Heiner Boeing, Antonia Trichopoulou, Eleni-Maria Papatesta, Carlo La Vecchia, Domenico Palli, Sabina Sieri, Rosario Tumino, Carlotta Sacerdote, Amalia Mattiello, N. Charlotte Onland-Moret, Petra H. Peeters, H.Bas. Bueno-de-Mesquita, Elisabete Weiderpass, J. Ramón Quirós, Eric J. Duell, Maria-Jose Sánchez, Carmen Navarro, Eva Ardanaz, Nerea Larrañaga, Björn Nodin, Karin Jirström, Annika Idahl, Eva Lundin, Kay-Tee Khaw, Ruth C. Travis, Marc Gunter, Mattias Johansson, Laure Dossus, Melissa A. Merritt, Elio Riboli, Kathryn L. Terry, Daniel W. Cramer, and Rudolf Kaaks
International Journal of Cancer, 2017
[4]
FAN YANG, ZHI-DE HU, YINGJIAN CHEN, and CHENG-JIN HU
Biomedical Reports, 2016, Volume 4, Number 6, Page 681
[5]
Renée Turzanski Fortner, Antje Damms-Machado, and Rudolf Kaaks
Gynecologic Oncology, 2017
[6]
KRISTIAN MADEIRA, EDUARDO R. DONDOSSOLA, BRUNA F. DE FARIAS, CARLA S. SIMON, MARIA C.M. ALEXANDRE, BRUNO R. SILVA, and MARIA INÊS ROSA
Anais da Academia Brasileira de Ciências, 2016, Volume 88, Number 2, Page 923
[7]
Zhi-De Hu, Ting-Ting Wei, Min Yang, Ning Ma, Qing-Qin Tang, Bao-Dong Qin, Hai-Tao Fu, Ren-Qian Zhong, and Gianpaolo Papaccio
PLOS ONE, 2015, Volume 10, Number 5, Page e0126444
[8]
Zhu Lan, Faping Wang, Xiuzhang Yu, Xi Zeng, and Mingrong Xi
International Journal of Gynecological Cancer, 2016, Volume 26, Number 8, Page 1366
[9]
Yuxuan Wang, Karin Sundfeldt, Constantina Mateoiu, Ie-Ming Shih, Robert J Kurman, Joy Schaefer, Natalie Silliman, Isaac Kinde, Simeon Springer, Michael Foote, Björg Kristjansdottir, Nathan James, Kenneth W Kinzler, Nickolas Papadopoulos, Luis A Diaz, and Bert Vogelstein
eLife, 2016, Volume 5
[10]
Ana Carolina B. Stefanini, Bianca Rodrigues da Cunha, Tiago Henrique, and Eloiza H. Tajara
Disease Markers, 2015, Volume 2015, Page 1
[11]
Zhu Lan, Dan Fu, Xiuzhang Yu, and Mingrong Xi
Familial Cancer, 2016, Volume 15, Number 2, Page 221
[12]
Jian-Xiang Shi, Jie-Jie Qin, Hua Ye, Peng Wang, Kai-Juan Wang, and Jian-Ying Zhang
Expert Review of Molecular Diagnostics, 2015, Page 1
[13]
Ayala Tamir, Ushma Jag, Sreeja Sarojini, Craig Schindewolf, Takemi Tanaka, Rajendra Gharbaran, Hiren Patel, Anil Sood, Wei Hu, Ruzeen Patwa, Patrick Blake, Polina Chirina, Jin Oh Jeong, Heejin Lim, Andre Goy, Andrew Pecora, and K Stephen Suh
Journal of Ovarian Research, 2014, Volume 7, Number 1
[14]
Yue-Dong Wang, He Chen, Hui-Qiag Liu, and Min Hao
Tumor Biology, 2014, Volume 35, Number 12, Page 11799

Comments (0)

Please log in or register to comment.
Log in